AstraZeneca readies for CJEU ruling in generics case
Managing IP provides a guide to the Court of Justice’s ruling in a case between AstraZeneca and generic-manufacturers about what constitutes abuse of a dominant position in the pharmaceutical sector
What's the case about?
AstraZeneca makes and markets a product to treat gastrointestinal conditions under the name Losec. In 1999, Generics (UK) Ltd and Scandinavian Pharmaceuticals Generics AB complained to the European Commission that AstraZeneca had behaved in a way...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.